News
- Elisigen Closes Series C Financing of KRW 42 Billion
- Neuracle Genetics Rebrands as 'Elisigen'
- Neuracle Genetics Completes North American Phase 1/2a Dosing for NG101 (20 Participants)
- Neuracle Genetics Announces Completion of Dosing for Phase 1/2a SENSE Study of NG101
- Neuracle Genetics Announces Positive Interim Phase 1/2a Data for NG101, Showing 91% Reduction in Treatment Burden for Patients with Wet AMD
- Neuracle Genetics' wet AMD Gene Therapy Selected for KDDF National New Drug Development Project
- Neuracle Genetics' NG101 Granted FDA Fast Track Designation for wet AMD
- Neuracle Genetics' NG101 Receives FDA Fast Track Designation and Completes Dosing for Cohort 1
- Neuracle Genetics Receives Health Canada Approval for NG101 Phase 1/2a Clinical Trial